Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients
Sponsor: Dow University of Health Sciences
Summary
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It\'s an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.
Official title: Comparison Between Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo - a Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-01-01
Completion Date
2027-03-30
Last Updated
2025-03-11
Healthy Volunteers
No
Conditions
Interventions
Apremilast with NB-UVB
Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
NB-UVB
NBUVB only will be given twice per week for 8 months
Locations (1)
Dow International Medical College , DUHS
Karachi, Sindh, Pakistan